SA
Go ProLog In
VRDN
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
16 analysts·Moderate coverage
70
Score
13 Buy (81%)3 Hold (19%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1381%
Hold
319%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$26.00
+62.4%
Consensus
$36.50
+128.0%
Bull
$50.00
+212.3%
12-Month Target Range16 analysts
$26.00$36.50$50.00
Current $16.01Consensus
Current Price
$16.01
Upside to Consensus
$20.49

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+431.08%
EPS—
FY2028
Rev+137.23%
EPS—
FY2029
Rev+47.72%
EPS—

Earnings Surprises

Recent Analyst Actions

May 15, 2026Evercore ISI
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
Target:$26.00
+54.2%from $16.86
May 13, 2026Stifel Nicolaus
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
Target:$39.00
+132.6%from $16.77
May 6, 2026RBC Capital
Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
Target:$34.00
+81.3%from $18.75
Apr 21, 2026Truist Financial
Viridian Therapeutics price target lowered to $33 from $36 at Truist
Target:$33.00
+127.6%from $14.50
Apr 8, 2026Truist Financial
Viridian Therapeutics price target lowered to $36 from $40 at Truist
Target:$36.00
+148.8%from $14.47
Apr 8, 2026Wedbush
Viridian Therapeutics price target lowered to $31 from $37 at Wedbush
Target:$31.00
+114.2%from $14.47
Feb 26, 2026Jefferies
Viridian Therapeutic (VRDN) PT Raised to $45 at Jefferies
Target:$45.00
+56.2%from $28.80
Jan 28, 2026Evercore ISI
Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI
Target:$45.00
+35.8%from $33.14
Jan 20, 2026Evercore ISI
Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI
Target:$44.00
+34.8%from $32.63
Jan 7, 2026UBS
Viridian Therapeutics initiated with a Buy at UBS
Target:$50.00
+62.2%from $30.82
Dec 3, 2025William Blair
Viridian Therapeutics initiated with an Outperform at William Blair
Target:$47.00
+54.5%from $30.43
Nov 24, 2025Truist Financial
Viridian Therapeutics initiated with a Buy at Truist
Target:$41.00
+35.1%from $30.34
Nov 6, 2025RBC Capital
Viridian Therapeutics price target raised to $45 from $41 at RBC Capital
Target:$45.00
+63.6%from $27.50
Nov 6, 2025Goldman Sachs
Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs
Target:$40.00
+42.3%from $28.11
Nov 5, 2025Stifel Nicolaus
Viridian Therapeutic (VRDN) PT Raised to $48 at Stifel
Target:$48.00
+98.0%from $24.24
Oct 21, 2025Oppenheimer
Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer
Target:$36.00
+47.0%from $24.48
Oct 21, 2025H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Target:$34.00
+41.1%from $24.09
Nov 12, 2024Stifel Nicolaus
Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel
Target:$41.00
+259.3%from $11.41
Sep 13, 2024RBC Capital
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
Target:$44.00
+325.1%from $10.35
Sep 11, 2024Needham
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
Target:$38.00
+299.6%from $9.51
Sep 11, 2024B.Riley Financial
Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
Target:$22.00
+14.3%from $19.24
Sep 10, 2024Stifel Nicolaus
Viridian Therapeutics price target raised to $40 from $33 at Stifel
Target:$40.00
+360.8%from $8.68
Sep 10, 2024BTIG
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
Target:$56.00
+548.1%from $8.64
Aug 14, 2024Goldman Sachs
Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Target:$25.00
+76.3%from $14.18
Jun 11, 2024RBC Capital
RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
Target:$35.00
+440.1%from $6.48

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance